Comparison of the D 1 dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease

Psychopharmacology

Volumn 222, Issue 1, 2012, Pages 81-87

  McCorvy, John D ^a   Watts, Val J ^a   Nichols, David E ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

6 Hydroxydopamine; Contralateral rotation; Dihydrexidine; Dopamine D 1 receptor; Doxanthrine; Parkinson's disease; Rat

Indexed keywords

APOMORPHINE; DIHYDREXIDINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOXANTHRINE; OXIDOPAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAPERITONEAL; MALE; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PHENANTHRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1;

EID: 84861840044     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2625-5     Document Type: Article

References (30)

1. Asin KE, Wirtshafter D (1993) Effects of repeated dopamine D1 receptor stimulation on rotation and c-fos expression. Eur J Pharmacol 235:167-168 (Pubitemid 23124089)
2. Bonuccelli U, Pavese N (2006) Dopamine agonists in the treatment of Parkinson's disease. Expert Rev Neurother 6:81-89
3. Braun A, Fabbrini G, Mouradian MM, Serrati C, Barone P, Chase TN (1987) Selective D-1 dopamine receptor agonist treatment of Parkinson's disease. J Neural Transm 68:41-50
4. Brewster WK, Nichols DE, Riggs RM, Mottola DM, Lovenberg TW, Lewis MH, Mailman RB (1990) Trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a] phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem 33:1756-1764 (Pubitemid 20180639)
5. Chopin P, Colpaert FC,MarienM(1999) Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J Pharmacol Exp Ther 288:798-804 (Pubitemid 29119697)
6. Cueva JP, Giorgioni G, Grubbs RA, Chemel BR,Watts VJ, Nichols DE (2006) trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno [3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist. J Med Chem 49:6848-6857
7. Deumens R, Blokland A, Prickaerts J (2002) Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175:303-317
8. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351:2498-2508
9. Foltynie T, Brayne C, Barker RA (2002) The heterogeneity of idiopathic Parkinson's disease. J Neurol 249:138-145 (Pubitemid 34143467)
10. Gottwald MD, Aminoff MJ (2011) Therapies for dopaminergicinduced dyskinesias in Parkinson disease. Ann Neurol 69:919-927
11. Hickey P, Stacy M (2011) Available and emerging treatments for Parkinson's disease: a review. Drug Des Devel Ther 5:241-254
12. Jenner P (2008) Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann Neurol 64(Suppl 2):S16-S29
13. Johnson BJ, Peacock V, Schneider JS (1995) Dihydrexidine, a full D1 dopamine receptor agonist, induces rotational asymmetry in hemiparkinsonian monkeys. Pharmacol Biochem Behav 51:617-622
14. Kebabian JW, Britton DR, DeNinno MP, Perner R, Smith L, Jenner P, Schoenleber R, Williams M (1992) A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. Eur J Pharmacol 229:203-209 (Pubitemid 23015825)
15. Lahti RA, Roberts RC, Tamminga CA (1995) D2-family receptor distribution in human postmortem tissue: an autoradiographic study. Neuroreport 6:2505-2512
16. Lewis SJ, Dove A, Robbins TW, Barker RA, Owen AM (2003) Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 23:6351-6356 (Pubitemid 36875637)
17. Lin CW, Bianchi BR, Miller TR, Stashko MA, Wang SS, Curzon P, Bednarz L, Asin KE, Britton DR (1996) Persistent activation of the dopamine D1 receptor contributes to prolonged receptor desensitization: studies with A-77636. J Pharmacol Exp Ther 276:1022-1029
18. Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E (2011) Priorities in Parkinson's disease research. Nat Rev Drug Discov 10:377-393
19. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic, San Diego
20. Perez-Lloret S, Rascol O (2010) Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease. CNS Drugs 24:941-968
21. Przybyla JA, Cueva JP, Chemel BR, Hsu KJ, Riese DJ, McCorvy JD, Chester JA, Nichols DE, Watts VJ (2009) Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors. Eur Neuropsychopharmacol 19:138-146
22. Riekkinen M, Jakala P, Kejonen K, Riekkinen P Jr (1999) The alpha2 agonist, clonidine, improves spatial working performance in Parkinson's disease. Neuroscience 92:983-989 (Pubitemid 29287543)
23. Robin M, Forler C, Palfreyman MG (1985) Effect of chronic apomorphine on the development of denervation supersensitivity. Pharmacol Biochem Behav 22:547-551 (Pubitemid 15108231)
24. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA (2009) Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 8:1128-1139
25. Silver D (2006) Impact of functional age on the use of dopamine agonists in patients with Parkinson disease. Neurologist 12:214-223
26. Taylor JR, Lawrence MS, Redmond DE Jr, Elsworth JD, Roth RH, Nichols DE, Mailman RB (1991) Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur J Pharmacol 199:389-391
27. Tompson D, Oliver-Willwong R (2009) Pharmacokinetic and pharmaco-dynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease. Clin Neuropharmacol 32:140-148
28. Ungerstedt U (1976) 6-Hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. Pharmacol Ther B 2:37-40
29. Wooten GF (1997) Functional anatomical and behavioral consequences of dopamine receptor stimulation. Ann N YAcad Sci 835:153-156
30. Yoshikawa T, Yoshida N, Hosoki K (1996) Involvement of dopamine D3 receptors in the area postrema in R(+)-7-OH-DPAT-induced emesis in the ferret. Eur J Pharmacol 301:143-149